Let's take a detailed look at the dangers of using Ozempic: Reports link Ozempic to blindness and NAIOD, making it a risky ...

their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), after getting FDA approval for the would-be blockbuster. The US approval is the first in ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved ... made today’s approval possible.” Both drugs, administered ...

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025Cyprium is eligible to receive royalties and up to $129 ...

NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease This is the 2nd ...

US FDA grants orphan drug designation to NMD Pharma’s NMD670 to treat patients with Charcot-Marie-tooth disease: Aarhus, Denmark Tuesday, January 7, 2025, 16:00 Hrs [IST] NMD Ph ...

The focus of traditional treatments on the symptoms rather than the condition has unfortunately made neuropathy a ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Type 1.5 diabetes is found in adults over 30 and is often mistaken for type 2, but people with this condition are not necessarily overweight, and oral medications and lifestyle changes have no effect.

Paralytic drugs, or neuromuscular blocking agents (NMBAs), are powerful muscle relaxants used to prevent muscle movement during surgical procedures. They're also used during critical care, such as ...